The biotech drug development process working in tandem with the federal regulatory processes in place is slow when compared to other industries . So from an investor’s perspective, especially if this is someone’s first small biotech experience this is a very slow process. But when you look at Leronlimab , it is zipping thru phase 3 for those of us who have been involved professionally in this industry.
It’s only been in this phase for barely 7 months and the end is in reach. It’s always good to take a step back and put this fact in perspective . If this drug was a stinker for Covid , it would have been nixed a long time ago. But it has leaped each hurdle along the way and is coming to the finish line. Personally , I don’t go out of my way to look at the stock price because volume has been consistently low and will remain so until there is some form of approval, EAM, or EUA...so up,or down 20 points to me isn’t earth shattering because I am not selling. Period...there is too much opportunity with HIV, Cancer, and a covid , just to name a few.